A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

268

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Emraclidine
DRUG: Placebo

Sponsor

AbbVie